FCM
CLLS

Farallon Capital Management’s Cellectis CLLS Stock Holding History

Farallon Capital Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-385,000
Closed -$11M – 82
2017
Q3 		$11M Buy
+385,000
New +$9.96M 0.1% 69

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Farallon Capital Management's CLLS Position: Q4 2017 in Review

Farallon Capital Management sold out of Cellectis (CLLS) in Q4 2017, closing a stake of 385,000 shares — an estimated $11M sold.

Farallon Capital Management first reported a position in CLLS in Q3 2017 and held it in 1 quarter. The position peaked at $11M in Q3 2017. 57 funds tracked by Wall St. Rank hold CLLS as of Q4 2017.

  • Farallon Capital Management reported no remaining Cellectis position as of Q4 2017 after selling out during the quarter.
  • Farallon Capital Management sold 385,000 Cellectis shares in Q4 2017, an estimated $11M.
  • Farallon Capital Management first reported a position in Cellectis in Q3 2017 and held it in 1 quarter.
  • Farallon Capital Management's Cellectis position peaked at $11M in Q3 2017.
  • 57 funds tracked by Wall St. Rank held Cellectis as of Q4 2017.

Based on Farallon Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.